Publication:
Target blood pressure and control status in Asia

dc.contributor.authorYook Chin Chiaen_US
dc.contributor.authorKazuomi Karioen_US
dc.contributor.authorYuda Turanaen_US
dc.contributor.authorJennifer Nailesen_US
dc.contributor.authorJam Chin Tayen_US
dc.contributor.authorSaulat Siddiqueen_US
dc.contributor.authorSungha Parken_US
dc.contributor.authorJinho Shinen_US
dc.contributor.authorPeera Buranakitjaroenen_US
dc.contributor.authorChen Huan Chenen_US
dc.contributor.authorRomeo Divinagraciaen_US
dc.contributor.authorSatoshi Hoshideen_US
dc.contributor.authorHuynh Van Minhen_US
dc.contributor.authorJorge Sisonen_US
dc.contributor.authorArieska Ann Soenartaen_US
dc.contributor.authorGuru Prasad Sogunuruen_US
dc.contributor.authorApichard Sukonthasarnen_US
dc.contributor.authorBoon Wee Teoen_US
dc.contributor.authorNarsingh Vermaen_US
dc.contributor.authorYuqing Zhangen_US
dc.contributor.authorTzung Dau Wangen_US
dc.contributor.authorJi Guang Wangen_US
dc.contributor.otherUniversity Medicine and Pharmacy, Hue Universityen_US
dc.contributor.otherDe La Salle Health Sciences Instituteen_US
dc.contributor.otherSunway Universityen_US
dc.contributor.otherHanyang University Medical Centeren_US
dc.contributor.otherJichi Medical Universityen_US
dc.contributor.otherYonsei University Health Systemen_US
dc.contributor.otherShanghai Jiao Tong University School of Medicineen_US
dc.contributor.otherMadras Institute of Orthopaedics and Traumatology Hospitalsen_US
dc.contributor.otherNational Taiwan University Hospitalen_US
dc.contributor.otherKathmandu Universityen_US
dc.contributor.otherUniversity of the East Ramon Magsaysay Memorial Medical Centeren_US
dc.contributor.otherFatima Memorial Hospitalen_US
dc.contributor.otherNational Yang-Ming University Taiwanen_US
dc.contributor.otherUniversitas Katolik Indonesia Atma Jayaen_US
dc.contributor.otherUniversitas Indonesiaen_US
dc.contributor.otherUniversity of Malayaen_US
dc.contributor.otherFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Collegeen_US
dc.contributor.otherYong Loo Lin School of Medicineen_US
dc.contributor.otherKing George's Medical Universityen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherBangkok Hospital Chiang Maien_US
dc.date.accessioned2020-05-05T05:42:19Z
dc.date.available2020-05-05T05:42:19Z
dc.date.issued2020-03-01en_US
dc.description.abstract© 2019 Wiley Periodicals, Inc. It is widely accepted that hypertension constitutes a significant cardiovascular risk factor and that treating high blood pressure (BP) effectively reduces cardiovascular risk. An important issue in Asia is not just the high prevalence of hypertension, particularly in some countries, but also the low level of awareness and treatment rates in many regions. The 2017 update of the American College of Cardiology/American Heart Association hypertension guidelines raised the question about which BP threshold should be used to diagnose and treat hypertension. Although there is a theoretical rationale for a stricter BP criterion in Asia given the ethnic-specific features of hypertension in the region, the majority of countries in Asia have retained a diagnostic BP threshold of ≥140/90 mm Hg. Although lowering thresholds might make theoretical sense, this would increase the prevalence of hypertension and also markedly reduce BP control rates. In addition, there are currently no data from robust randomized clinical trials of the benefits of the lower targets in preventing cardiovascular disease and reducing cardiovascular risk, particularly in high-risk patients and especially for Asian populations. There is also no defined home BP treatment target level for an office BP treatment target of 130/80 mm Hg. However, in this regard, in the interim, lifestyle modifications, including reducing body weight and salt intake, should form an important part of hypertension management strategies in Asia, while studies on treating at lower BP threshold level in Asians and getting to lower BP targets will be helpful to inform and optimize the management of hypertension in the region.en_US
dc.identifier.citationJournal of Clinical Hypertension. Vol.22, No.3 (2020), 344-350en_US
dc.identifier.doi10.1111/jch.13714en_US
dc.identifier.issn17517176en_US
dc.identifier.issn15246175en_US
dc.identifier.other2-s2.0-85075450586en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/54630
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075450586&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleTarget blood pressure and control status in Asiaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075450586&origin=inwarden_US

Files

Collections